Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 99 entries
Sorted by: Best Match Show Resources per page
Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny.

ISRN urology

Morris BJ, Hankins CA, Tobian AA, Krieger JN, Klausner JD.
PMID: 24944836
ISRN Urol. 2014 May 13;2014:684706. doi: 10.1155/2014/684706. eCollection 2014.

We critically evaluate a recent article by Van Howe involving 12 meta-analyses that concludes, contrary to current evidence, that male circumcision increases the risk of various common sexually transmitted infections (STIs). Our detailed scrutiny reveals that these meta-analyses (1)...

Cite
Morris BJ, Hankins CA, Tobian AA, et al. Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny. ISRN Urol. 2014;2014:684706doi: 10.1155/2014/684706.
Morris, B. J., Hankins, C. A., Tobian, A. A., Krieger, J. N., & Klausner, J. D. (2014). Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny. ISRN urology, 2014684706. https://doi.org/10.1155/2014/684706
Morris, Brian J, et al. "Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny." ISRN urology vol. 2014 (2014): 684706. doi: https://doi.org/10.1155/2014/684706
Morris BJ, Hankins CA, Tobian AA, Krieger JN, Klausner JD. Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny. ISRN Urol. 2014 May 13;2014:684706. doi: 10.1155/2014/684706. eCollection 2014. PMID: 24944836; PMCID: PMC4040210.
Copy Download .nbib Format: NLM
A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers.

Neurobehavioral HIV medicine

Levine AJ, Palomo M, Hinkin CH, Valdes-Sueiras M, Lopez E, Mathisen G, Donovan S, Singer EJ.
PMID: 26448691
Neurobehav HIV Med. 2011;3:79-86. doi: 10.2147/NBHIV.S22553.

BACKGROUND: A substantial number of Spanish-speaking individuals from Mexico and Central America are now living in the United States. These individuals are at heightened risk for HIV infection and, due to late diagnosis and limited resources, for HIV-associated neurocognitive...

Cite
Levine AJ, Palomo M, Hinkin CH, et al. A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers. Neurobehav HIV Med. 2011;3:79-86doi: 10.2147/NBHIV.S22553.
Levine, A. J., Palomo, M., Hinkin, C. H., Valdes-Sueiras, M., Lopez, E., Mathisen, G., Donovan, S., & Singer, E. J. (2011). A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers. Neurobehavioral HIV medicine, 379-86. https://doi.org/10.2147/NBHIV.S22553
Levine, Andrew J, et al. "A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers." Neurobehavioral HIV medicine vol. 3 (2011): 79-86. doi: https://doi.org/10.2147/NBHIV.S22553
Levine AJ, Palomo M, Hinkin CH, Valdes-Sueiras M, Lopez E, Mathisen G, Donovan S, Singer EJ. A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers. Neurobehav HIV Med. 2011;3:79-86. doi: 10.2147/NBHIV.S22553. PMID: 26448691; PMCID: PMC4593057.
Copy Download .nbib Format: NLM
Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men.

Open forum infectious diseases

Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ.
PMID: 25884003
Open Forum Infect Dis. 2015 Jan 01;2(1):ofu114. doi: 10.1093/ofid/ofu114. eCollection 2015 Jan.

Background.  Stimulant-using men who have sex with men (MSM) are at high risk of human immunodeficiency virus (HIV) acquisition. Contingency Management (CM) is a robust substance abuse intervention that provides voucher-based incentives for stimulant-use abstinence. Methods.  We conducted a...

Cite
Landovitz RJ, Fletcher JB, Shoptaw S, et al. Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open Forum Infect Dis. 2015;2(1):ofu114doi: 10.1093/ofid/ofu114.
Landovitz, R. J., Fletcher, J. B., Shoptaw, S., & Reback, C. J. (2015). Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open forum infectious diseases, 2(1), ofu114. https://doi.org/10.1093/ofid/ofu114
Landovitz, Raphael J, et al. "Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men." Open forum infectious diseases vol. 2,1 (2015): ofu114. doi: https://doi.org/10.1093/ofid/ofu114
Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ. Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open Forum Infect Dis. 2015 Jan 01;2(1):ofu114. doi: 10.1093/ofid/ofu114. eCollection 2015 Jan. PMID: 25884003; PMCID: PMC4396429.
Copy Download .nbib Format: NLM
Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.

Computational statistics & data analysis

Kitchen CM, Kroll J, Kuritzkes DR, Bloomquist E, Deeks SG, Suchard MA.
PMID: 20442796
Comput Stat Data Anal. 2009 Jan 15;53(3):766-775. doi: 10.1016/j.csda.2008.06.007.

Enfuvirtide (ENF) is a fusion inhibitor that prevents the entry of HIV virions into target cells. Studying the characteristics of viral evolution during treatment and after a treatment interruption can lend insight into the mechanisms of viral evolution and...

Cite
Kitchen CM, Kroll J, Kuritzkes DR, et al. Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Comput Stat Data Anal. 2009;53(3):766-775doi: 10.1016/j.csda.2008.06.007.
Kitchen, C. M., Kroll, J., Kuritzkes, D. R., Bloomquist, E., Deeks, S. G., & Suchard, M. A. (2009). Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Computational statistics & data analysis, 53(3), 766-775. https://doi.org/10.1016/j.csda.2008.06.007
Kitchen, Christina M R, et al. "Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment." Computational statistics & data analysis vol. 53,3 (2009): 766-775. doi: https://doi.org/10.1016/j.csda.2008.06.007
Kitchen CM, Kroll J, Kuritzkes DR, Bloomquist E, Deeks SG, Suchard MA. Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Comput Stat Data Anal. 2009 Jan 15;53(3):766-775. doi: 10.1016/j.csda.2008.06.007. PMID: 20442796; PMCID: PMC2862497.
Copy Download .nbib Format: NLM
Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

American journal of neurodegenerative disease

Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, Martinez-Maza O, Chattopadhyay M, La Cava A.
PMID: 23383400
Am J Neurodegener Dis. 2012;1(3):305-15. Epub 2012 Nov 21.

Patients with amyotrophic lateral sclerosis (ALS) have evidence of chronic inflammation demonstrated by infiltration of the gray matter by inflammatory macrophages, IL17A-positive T cells, and mast cells. Increased serum levels of IL6 and IL17A have been detected in sporadic...

Cite
Mizwicki MT, Fiala M, Magpantay L, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305-15
Mizwicki, M. T., Fiala, M., Magpantay, L., Aziz, N., Sayre, J., Liu, G., Siani, A., Chan, D., Martinez-Maza, O., Chattopadhyay, M., & La Cava, A. (2012). Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. American journal of neurodegenerative disease, 1(3), 305-15.
Mizwicki, Mathew T, et al. "Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling." American journal of neurodegenerative disease vol. 1,3 (2012): 305-15.
Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, Martinez-Maza O, Chattopadhyay M, La Cava A. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305-15. Epub 2012 Nov 21. PMID: 23383400; PMCID: PMC3560466.
Copy Download .nbib Format: NLM
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.

Frontiers in immunology

Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML.
PMID: 29379493
Front Immunol. 2018 Jan 04;8:1751. doi: 10.3389/fimmu.2017.01751. eCollection 2017.

The remarkable progress in engineering and clinical development of therapeutic antibodies in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by the United States Food and Drug Administration (FDA) of...

Cite
Almagro JC, Daniels-Wells TR, Perez-Tapia SM, et al. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2018;8:1751doi: 10.3389/fimmu.2017.01751.
Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L. (2017). Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Frontiers in immunology, 81751. https://doi.org/10.3389/fimmu.2017.01751
Almagro, Juan C, et al. "Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy." Frontiers in immunology vol. 8 (2017): 1751. doi: https://doi.org/10.3389/fimmu.2017.01751
Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2018 Jan 04;8:1751. doi: 10.3389/fimmu.2017.01751. eCollection 2017. PMID: 29379493; PMCID: PMC5770808.
Copy Download .nbib Format: NLM
Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Science immunology

Kim JT, Liu Y, Kulkarni RP, Lee KK, Dai B, Lovely G, Ouyang Y, Wang P, Yang L, Baltimore D.
PMID: 28733470
Sci Immunol. 2017 Jul 21;2(13). doi: 10.1126/sciimmunol.aal1329.

Dendritic cell (DC) activation and antigen presentation are critical for efficient priming of T cell responses. Here, we study how lentiviral vectors (LVs) deliver antigen and activate DCs to generate T cell immunization in vivo. We report that antigenic...

Cite
Kim JT, Liu Y, Kulkarni RP, et al. Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci Immunol. 2017;2(13)doi: 10.1126/sciimmunol.aal1329.
Kim, J. T., Liu, Y., Kulkarni, R. P., Lee, K. K., Dai, B., Lovely, G., Ouyang, Y., Wang, P., Yang, L., & Baltimore, D. (2017). Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Science immunology, 2(13), . https://doi.org/10.1126/sciimmunol.aal1329
Kim, Jocelyn T, et al. "Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation." Science immunology vol. 2,13 (2017). doi: https://doi.org/10.1126/sciimmunol.aal1329
Kim JT, Liu Y, Kulkarni RP, Lee KK, Dai B, Lovely G, Ouyang Y, Wang P, Yang L, Baltimore D. Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci Immunol. 2017 Jul 21;2(13). doi: 10.1126/sciimmunol.aal1329. PMID: 28733470; PMCID: PMC5845465.
Copy Download .nbib Format: NLM
Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi.

Journal of clinical research in HIV AIDS and prevention

Gibb J, Chitsulo J, Chipungu C, Chivwara M, Schooley A, Hoffman RM.
PMID: 28702463
J Clin Res HIV AIDS Prev. 2017;3(1). doi: 10.14302/issn.2324-7339.jcrhap-17-1468. Epub 2017 Mar 14.

Successful viral load programs rely on the presence of data systems and high quality of patient data. Using a cohort of 49 patients at Partners in Hope, a large, urban HIV clinic in Malawi, we performed a quality improvement...

Cite
Gibb J, Chitsulo J, Chipungu C, et al. Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi. J Clin Res HIV AIDS Prev. 2017;3(1)doi: 10.14302/issn.2324-7339.jcrhap-17-1468.
Gibb, J., Chitsulo, J., Chipungu, C., Chivwara, M., Schooley, A., & Hoffman, R. M. (2017). Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi. Journal of clinical research in HIV AIDS and prevention, 3(1), . https://doi.org/10.14302/issn.2324-7339.jcrhap-17-1468
Gibb, Jean, et al. "Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi." Journal of clinical research in HIV AIDS and prevention vol. 3,1 (2017). doi: https://doi.org/10.14302/issn.2324-7339.jcrhap-17-1468
Gibb J, Chitsulo J, Chipungu C, Chivwara M, Schooley A, Hoffman RM. Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi. J Clin Res HIV AIDS Prev. 2017;3(1). doi: 10.14302/issn.2324-7339.jcrhap-17-1468. Epub 2017 Mar 14. PMID: 28702463; PMCID: PMC5502771.
Copy Download .nbib Format: NLM
Experimental Approaches for Eliminating Latent HIV.

Forum on immunopathological diseases and therapeutics

Marsden MD, Zack JA.
PMID: 28191361
For Immunopathol Dis Therap. 2015;6(1):91-99. doi: 10.1615/forumimmundisther.2016015242.

Antiretroviral therapy (ART) can reduce HIV viral loads to undetectable levels and prevent disease progression. However, HIV persists in rare cellular reservoirs within ART-treated patients and rapidly reemerges if ART is stopped. Latently infected CD4

Cite
Marsden MD, Zack JA. Experimental Approaches for Eliminating Latent HIV. For Immunopathol Dis Therap. 2015;6(1):91-99doi: 10.1615/forumimmundisther.2016015242.
Marsden, M. D., & Zack, J. A. (2015). Experimental Approaches for Eliminating Latent HIV. Forum on immunopathological diseases and therapeutics, 6(1), 91-99. https://doi.org/10.1615/forumimmundisther.2016015242
Marsden, Matthew D, and Zack, Jerome A. "Experimental Approaches for Eliminating Latent HIV." Forum on immunopathological diseases and therapeutics vol. 6,1 (2015): 91-99. doi: https://doi.org/10.1615/forumimmundisther.2016015242
Marsden MD, Zack JA. Experimental Approaches for Eliminating Latent HIV. For Immunopathol Dis Therap. 2015;6(1):91-99. doi: 10.1615/forumimmundisther.2016015242. PMID: 28191361; PMCID: PMC5302864.
Copy Download .nbib Format: NLM
Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease.

Cellular and molecular gastroenterology and hepatology

Li X, LeBlanc J, Elashoff D, McHardy I, Tong M, Roth B, Ippoliti A, Barron G, McGovern D, McDonald K, Newberry R, Graeber T, Horvath S, Goodglick L, Braun J.
PMID: 28174738
Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):567-583. doi: 10.1016/j.jcmgh.2016.05.003. eCollection 2016 Sep.

BACKGROUND & AIMS: Interactions between mucosal cell types, environmental stressors, and intestinal microbiota contribute to pathogenesis in inflammatory bowel disease (IBD). Here, we applied metaproteomics of the mucosal-luminal interface to study the disease-related biology of the human colonic mucosa.METHODS:...

Cite
Li X, LeBlanc J, Elashoff D, et al. Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2016;2(5):567-583doi: 10.1016/j.jcmgh.2016.05.003.
Li, X., LeBlanc, J., Elashoff, D., McHardy, I., Tong, M., Roth, B., Ippoliti, A., Barron, G., McGovern, D., McDonald, K., Newberry, R., Graeber, T., Horvath, S., Goodglick, L., & Braun, J. (2016). Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cellular and molecular gastroenterology and hepatology, 2(5), 567-583. https://doi.org/10.1016/j.jcmgh.2016.05.003
Li, Xiaoxiao, et al. "Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease." Cellular and molecular gastroenterology and hepatology vol. 2,5 (2016): 567-583. doi: https://doi.org/10.1016/j.jcmgh.2016.05.003
Li X, LeBlanc J, Elashoff D, McHardy I, Tong M, Roth B, Ippoliti A, Barron G, McGovern D, McDonald K, Newberry R, Graeber T, Horvath S, Goodglick L, Braun J. Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):567-583. doi: 10.1016/j.jcmgh.2016.05.003. eCollection 2016 Sep. PMID: 28174738; PMCID: PMC5042708.
Copy Download .nbib Format: NLM
PD-1 blockade enhances the vaccination-induced immune response in glioma.

JCI insight

Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.
PMID: 27453950
JCI Insight. 2016 Jul 07;1(10). doi: 10.1172/jci.insight.87059.

DC vaccination with autologous tumor lysate has demonstrated promising results for the treatment of glioblastoma (GBM) in preclinical and clinical studies. While the vaccine appears capable of inducing T cell infiltration into tumors, the effectiveness of active vaccination in...

Cite
Antonios JP, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10)doi: 10.1172/jci.insight.87059.
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J., Moughon, D., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., Liau, L. M., & Prins, R. M. (2016). PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI insight, 1(10), . https://doi.org/10.1172/jci.insight.87059
Antonios, Joseph P, et al. "PD-1 blockade enhances the vaccination-induced immune response in glioma." JCI insight vol. 1,10 (2016). doi: https://doi.org/10.1172/jci.insight.87059
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07;1(10). doi: 10.1172/jci.insight.87059. PMID: 27453950; PMCID: PMC4951098.
Copy Download .nbib Format: NLM
Beyond the Primary Endpoint Paradigm: A Test of Intervention Effect in HIV Behavioral Intervention Trials with Numerous Correlated Outcomes.

Prevention science : the official journal of the Society for Prevention Research

Harwood JM, Weiss RE, Comulada WS.
PMID: 28434056
Prev Sci. 2017 Jul;18(5):526-533. doi: 10.1007/s11121-017-0788-y.

Behavioral interventions are increasingly based on holistic approaches to health with an understanding that health-related behaviors are linked. A motivating example is provided by the Philani study, an intervention trial conducted to improve the health of South African mothers...

Cite
Harwood JM, Weiss RE, Comulada WS. Beyond the Primary Endpoint Paradigm: A Test of Intervention Effect in HIV Behavioral Intervention Trials with Numerous Correlated Outcomes. Prev Sci. 2017;18(5):526-533doi: 10.1007/s11121-017-0788-y.
Harwood, J. M., Weiss, R. E., & Comulada, W. S. (2017). Beyond the Primary Endpoint Paradigm: A Test of Intervention Effect in HIV Behavioral Intervention Trials with Numerous Correlated Outcomes. Prevention science : the official journal of the Society for Prevention Research, 18(5), 526-533. https://doi.org/10.1007/s11121-017-0788-y
Harwood, Jessica M, et al. "Beyond the Primary Endpoint Paradigm: A Test of Intervention Effect in HIV Behavioral Intervention Trials with Numerous Correlated Outcomes." Prevention science : the official journal of the Society for Prevention Research vol. 18,5 (2017): 526-533. doi: https://doi.org/10.1007/s11121-017-0788-y
Harwood JM, Weiss RE, Comulada WS. Beyond the Primary Endpoint Paradigm: A Test of Intervention Effect in HIV Behavioral Intervention Trials with Numerous Correlated Outcomes. Prev Sci. 2017 Jul;18(5):526-533. doi: 10.1007/s11121-017-0788-y. PMID: 28434056; PMCID: PMC5627604.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 99 entries